Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Quoin Pharmaceuticals, Ltd. (QNRX)

6.23 +0.01 (+0.16%)
As of 12:39:29 PM EDT. Market Open.
Chart Range Bar
Loading chart for QNRX
  • Previous Close 6.22
  • Open 5.80
  • Bid 6.28 x 1000
  • Ask 7.50 x 100
  • Day's Range 5.75 - 6.49
  • 52 Week Range 3.25 - 41.80
  • Volume 161,465
  • Avg. Volume 737,603
  • Market Cap (intraday) 12.512M
  • Beta (5Y Monthly) 1.66
  • PE Ratio (TTM) --
  • EPS (TTM) -5.67
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 21.40

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

quoinpharma.com

4

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/1/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

QNRX
53.85%
MSCI WORLD (^990100-USD-STRD)
11.36%

1-Year Return

QNRX
15.53%
MSCI WORLD (^990100-USD-STRD)
0.00%

3-Year Return

QNRX
96.90%
MSCI WORLD (^990100-USD-STRD)
65.03%

5-Year Return

QNRX
99.99%
MSCI WORLD (^990100-USD-STRD)
56.54%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -5M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

-4M
-3M
-2M
-1M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

12.00
21.40 Average
6.23 Current
35.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/4/2026
Analyst LUCID CAPITAL MARKETS
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 30

Statistics

View More

Valuation Measures

Annual
As of 8/31/2026
  • Market Cap

    12.83M

  • Enterprise Value

    2.03M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.13

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -114.60%

  • Return on Equity (ttm)

    -575.73%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -18.67M

  • Diluted EPS (ttm)

    -5.67

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.8M

  • Total Debt/Equity (mrq)

    51.46%

  • Levered Free Cash Flow (ttm)

    -8M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

6.23 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: